2,6-Di-tert-butyl-4-(2'-thenoyl)phenol(R-830): a novel nonsteroidal anti-inflammatory agent with antioxidant properties.
R-830, a di-tert-butylphenol, has been shown to be anti-inflammatory in a number of animal models. These include conventional systems such as carrageenan-induced edema and adjuvant arthritis of the rat and ultraviolet-induced erythema in the guinea pig in which the acidic nonsteroidal anti-inflammatory drugs (e.g., indomethacin) are effective. The anti-inflammatory activity of R-830 has also been demonstrated in other models (e.g., graft vs. host reaction and reversed passive cutaneous Arthus reaction in the rat, contact sensitivity in the mouse) in which the acidic nonsteroidal drugs are not effective. In vitro, R-830 inhibits guinea pig lung lipoxygenase and bovine seminal vesicle cyclo-oxygenase. The antioxidant properties of R-830 were demonstrated in two in vitro systems. We speculate that the antioxidant activity of this molecule might be related to its unusual profile of pharmacological activity.
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology* / Q000633:toxicity; D000975:Antioxidants / Q000494:pharmacology*; D001169:Arthritis, Experimental / Q000188:drug therapy; D002084:Butylated Hydroxytoluene / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000633:toxicity; D003877:Dermatitis, Contact / Q000188:drug therapy; D004487:Edema / Q000188:drug therapy; D006087:Graft vs Host Reaction; D006099:Granuloma / Q000188:drug therapy; D016859:Lipoxygenase Inhibitors; D008297:Male; D010081:Oxazolone / Q000633:toxicity; D010323:Passive Cutaneous Anaphylaxis / Q000187:drug effects; D011453:Prostaglandins / Q000096:biosynthesis; D051381:Rats; D011919:Rats, Inbred Strains
D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D016859:Lipoxygenase Inhibitors; D011453:Prostaglandins; C037195:prifelone; D010081:Oxazolone; D002084:Butylated Hydroxytoluene